1446121-66-9

Upstream product

• 1446120-09-7 (4R,5S)-5-(benzyloxymethyl)-2,2,4-trimethyl-4-(4-methylpent-3-enyl)-1,3-dioxolane 
• 1446120-41-7 (R)-3-(tert-butyldimethylsilyloxy)-5-((4R,5S)-2,2,4-trimethyl-5-vinyl-1,3-dioxolan-4-yl)pentan-1-ol 
• 1446120-32-6 (R)-5-(2-((4R,5S)-5-(benzyloxymethyl)-2,2,4-trimethyl-1,3-dioxolan-4-yl)ethyl)-2,2,3,3,8,8,9,9-octamethyl-4,7-dioxa-3,8-disiladecane 
• 1446120-21-3 (E)-5-((4R,5S)-5-(benzyloxymethyl)-2,2,4-trimethyl-1,3-dioxolan-4-yl)pent-2-en-1-ol 
• 1446120-13-3 3-((4R,5S)-5-(benzyloxymethyl)-2,2,4-trimethyl-1,3-dioxolan-4-yl)propanal 
• 304465-95-0 (2S,3R)-1-(benzyloxy)-3,7-dimethyloct-6-ene-2,3-diol 
• 106-24-1 Geraniol 
• 1446120-44-0 (R)-3-(tert-butyldimethylsilyloxy)-5-((4R,5S)-2,2,4-trimethyl-5-vinyl-1,3-dioxolan-4-yl)pentanoic acid 
• 1446121-51-2 tert-butyl((1S,2S)-1-(4-methoxyphenyl)-2-methylbut-3-enyloxy)dimethylsilane 
• 1446121-44-3 (2S,3S)-3-(tert-butyldimethylsilyloxy)-3-(4-methoxyphenyl)-2-methylpropan-1-ol 
• 123-11-5 4-methoxy-benzaldehyde 
• 1446120-38-2 (R)-2,2,3,3,9,9,10,10-octamethyl-5-(2-((4R,5S)-2,2,4-trimethyl-5-vinyl-1,3-dioxolan-4-yl)ethyl)-4,8-dioxa-3,9-disilaundecane 
• 1446121-37-4 (S)-4-benzyl-3-((2R,3S)-3-(tert-butyldimethylsilyloxy)-3-(4-methoxyphenyl)-2-methylpropanoyl)oxazolidin-2-one 
• 1446120-35-9 ((4S,5R)-5-((R)-3,5-bis(tert-butyldimethylsilyloxy)pentyl)-2,2,5-tri-methyl-1,3-dioxolan-4-yl)methanol 

Downstream Products

• 1446121-78-3 (3R,6R,7S)-((1S,2S)-1-(4-methoxyphenyl)-2-methylbut-3-enyl) 3,6,7-tri-hydroxy-6-methylnon-8-enoate 
• 1446121-89-6 (4R,7R,8S,11RS₁₂S,E)-4,7,8-trihydroxy-12-(4-methoxyphenyl)-7,11-dimethyloxacyclododec-9-en-2-one 
• 1446121-99-8 (2S,3S,6S,7R,10R,E)-7,10-dihydroxy-2-(4-methoxyphenyl)-3,7-dimethyl-12-oxooxacyclododec-4-en-6-yl acetate 

Relevant academic research and scientific papers

Enantioselective synthesis of pladienolide B and truncated analogues as new anticancer agents

An enantioselective synthesis of natural anticancer macrolide pladienolide B is described. The synthetic highlights include Sharpless asymmetric epoxidation, ring closing metathesis (RCM), Ireland-Claisen rearrangement, Shi epoxidation, and Pd-catalyzed S